Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

K. J. Harrington; L. J. Billingham; T. B. Brunner; N. G. Burnet; C. S. Chan; P. Hoskin; R. I. MacKay; T. S. Maughan; J. MacDougall; W. G. McKenna; C. M. Nutting; A. Oliver; R. Plummer; I. J. Stratford; T. Illidge

doi:10.1038/bjc.2011.240

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

K. J. Harrington, L. J. Billingham, T. B. Brunner, N. G. Burnet, C. S. Chan, P. Hoskin, R. I. MacKay, T. S. Maughan, J. MacDougall, W. G. McKenna, C. M. Nutting, A. Oliver, R. Plummer, I. J. Stratford, T. Illidge

Research output: Contribution to journal › Article › peer-review

Abstract

There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. © 2011 Cancer Research UK All Rights Reserved.

Original language	English
Pages (from-to)	628-639
Number of pages	11
Journal	British Journal of Cancer
Volume	105
Issue number	5
DOIs	https://doi.org/10.1038/bjc.2011.240
Publication status	Published - 23 Aug 2011

Keywords

assessment
clinical
early
novel radiosensitisers
preclinical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2011.240

Cite this

Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., MacKay, R. I., Maughan, T. S., MacDougall, J., McKenna, W. G., Nutting, C. M., Oliver, A., Plummer, R., Stratford, I. J., & Illidge, T. (2011). Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer, 105(5), 628-639. https://doi.org/10.1038/bjc.2011.240

@article{3b28de5d12d54182aee3542d9655c0ff,

title = "Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers",

abstract = "There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. {\textcopyright} 2011 Cancer Research UK All Rights Reserved.",

keywords = "assessment, clinical, early, novel radiosensitisers, preclinical",

author = "Harrington, {K. J.} and Billingham, {L. J.} and Brunner, {T. B.} and Burnet, {N. G.} and Chan, {C. S.} and P. Hoskin and MacKay, {R. I.} and Maughan, {T. S.} and J. MacDougall and McKenna, {W. G.} and Nutting, {C. M.} and A. Oliver and R. Plummer and Stratford, {I. J.} and T. Illidge",

year = "2011",

month = aug,

day = "23",

doi = "10.1038/bjc.2011.240",

language = "English",

volume = "105",

pages = "628--639",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "5",

}

Harrington, KJ, Billingham, LJ, Brunner, TB, Burnet, NG, Chan, CS, Hoskin, P, MacKay, RI, Maughan, TS, MacDougall, J, McKenna, WG, Nutting, CM, Oliver, A, Plummer, R, Stratford, IJ & Illidge, T 2011, 'Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers', British Journal of Cancer, vol. 105, no. 5, pp. 628-639. https://doi.org/10.1038/bjc.2011.240

TY - JOUR

T1 - Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

AU - Harrington, K. J.

AU - Billingham, L. J.

AU - Brunner, T. B.

AU - Burnet, N. G.

AU - Chan, C. S.

AU - Hoskin, P.

AU - MacKay, R. I.

AU - Maughan, T. S.

AU - MacDougall, J.

AU - McKenna, W. G.

AU - Nutting, C. M.

AU - Oliver, A.

AU - Plummer, R.

AU - Stratford, I. J.

AU - Illidge, T.

PY - 2011/8/23

Y1 - 2011/8/23

N2 - There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. © 2011 Cancer Research UK All Rights Reserved.

AB - There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. © 2011 Cancer Research UK All Rights Reserved.

KW - assessment

KW - clinical

KW - early

KW - novel radiosensitisers

KW - preclinical

U2 - 10.1038/bjc.2011.240

DO - 10.1038/bjc.2011.240

M3 - Article

C2 - 21772330

SN - 0007-0920

VL - 105

SP - 628

EP - 639

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this